Abstract
Purpose
To investigate the expression pattern of miR-16 and miR-451 and evaluate their prognostic value in 180 GC patients undergoing surgery.
Methods
In our previous study, a panel of five circulating miRNAs (miR-16, miR-25, miR-92a, miR-451 and miR-486-5p) can be used as a potential biomarker for detecting of early-stage gastric carcinoma (GC). Tissue microarrays were constructed from 180 patients with GC after surgery. MiR-16 and miR-451 expression was detected by miRNA-locked nucleic acid in situ hybridization, and their relationship with clinicopathological parameters and overall survival was analyzed.
Results
MiR-16 expression was decreased in 30.6 % (55/180) of GC, increased in 54.4 % (98/180) and unchanged in 15.0 % (27/180), compared with paracancerous normal tissue (P < 0.001). MiR-451 expression was decreased in 17.8 % (32/180), increased in 62.8 % (113/180) and unchanged in 19.4 % (35/180) of GC, compared with paracancerous normal tissue (P < 0.001).Univariate analysis indicated that low miR-16 and miR-451 expression, tumor stage, tumor status, node status and tumor size were significant negative prognostic predictors for overall survival in patients with GC (P < 0.001, P < 0.001, P = 0.002, P < 0.001 and P = 0.001, respectively). Multivariate regression analysis demonstrated that stage [hazard ratio (HR) 1.80; 95 % confidence interval (CI) 1.0–3.26; P = 0.05], low expression of miR-16 (HR 2.26; 95 % CI 1.51–3.40; P < 0.001) and miR-451 (HR 2.01; 95 % CI 1.36–2.96; P < 0.001) predicted shorter OS, while tumor status (HR 1.59; 95 % CI 0.73–3.48 P = 0.242), lymph node metastasis (HR 1.41; 95 % CI 0.71–2.82; P = 0.326) and tumor size (HR 1.53; 95 % CI 0.92–2.55; P = 0.099) were not. Moreover, patients with both miR-16 and miR-451 high expression have better OS than those with two miRNAs unchanged or low expression in GC tissues. Patients with both miR-16 and miR-451 high have better OS than patients with single miR-451 high expression.
Conclusions
High expression of miR-16 and miR-451 was associated with longer OS in GC patients. Especially patients with miR-16 and miR-451 double high expression will predict better OS. MiR-16 and miR-451 may be used as novel makers to evaluate prognosis and provide a new treatment target in GC.
Similar content being viewed by others
References
Bandres E, Bitarte N, Arias F, Agorreta J, Fortes P, Agirre X et al (2009) microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. Clin Cancer Res 15(7):2281–2290
Cui L, Zhang X, Ye G, Zheng T, Song H, Deng H et al (2013) Gastric juice MicroRNAs as potential biomarkers for the screening of gastric cancer. Cancer 119(9):1618–1626
He C, Jiang H, Geng S, Sheng H, Shen X, Zhang X et al (2014) Expression and prognostic value of c-Myc and Fas (CD95/APO1) in patients with pancreatic cancer. Int J Clin Exp Pathol 7(2):742–750
Kang W, Tong JH, Lung RW, Dong Y, Zhao J, Liang Q et al (2015) Targeting of YAP1 by microRNA-15a and microRNA-16-1 exerts tumor suppressor function in gastric adenocarcinoma. Mol Cancer 14:52
Kogo R, Mimori K, Tanaka F, Komune S, Mori M (2011) Clinical significance of miR-146a in gastric cancer cases. Clin Cancer Res 17(13):4277–4284
Liu X, Kwong A, Sihoe A, Chu KM (2016) Plasma miR-940 may serve as a novel biomarker for gastric cancer. Tumour Biol 37(3):3589–3597
McLean MH, El-Omar EM (2014) Genetics of gastric cancer. Nat Rev Gastroenterol Hepatol 11(11):664–674
Peng Z, Zhang Y (2016) Propofol inhibits proliferation and accelerates apoptosis of human gastric cancer cells by regulation of microRNA-451 and MMP-2 expression. Genet Mol Res. doi:10.4238/gmr.15027078
Ren C, Wang W, Han C, Chen H, Fu D, Luo Y et al (2016) Expression and prognostic value of miR-92a in patients with gastric cancer. Tumour Biol 37(7):9483–9491
Riquelme I, Tapia O, Leal P, Sandoval A, Varga MG, Letelier P et al (2016) miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in gastric cancer through regulation of the PI3K/AKT/mTOR pathway. Cell Oncol (Dordr) 39(1):23–33
Rotkrua P, Shimada S, Mogushi K, Akiyama Y, Tanaka H, Yuasa Y (2013) Circulating microRNAs as biomarkers for early detection of diffuse-type gastric cancer using a mouse model. Br J Cancer 108(4):932–940
Rupaimoole R, Calin GA, Lopez-Berestein G, Sood AK (2016) miRNA deregulation in cancer cells and the tumor microenvironment. Cancer Discov 6(3):235–246
Su Z, Zhao J, Rong Z, Geng W, Wang Z (2015) MiR-451, a potential prognostic biomarker and tumor suppressor for gastric cancer. Int J Clin Exp Pathol 8(8):9154–9160
Svoronos AA, Engelman DM, Slack FJ (2016) OncomiR or tumor suppressor? The duplicity of microRNAs in cancer. Cancer Res 76(13):3666–3670
Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S et al (2010) Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol 11(2):136–146
Venturutti L, Cordo Russo RI, Rivas MA, Mercogliano MF, Izzo F, Oakley RH et al (2016) MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1. Oncogene. doi:10.1038/onc.2016.151
Wang F, Jiang C, Sun Q, Yan F, Wang L, Fu Z et al (2015a) miR-195 is a key regulator of Raf1 in thyroid cancer. Onco Targets Ther 8:3021–3028
Wang Y, Gao Y, Shi W, Zhai D, Rao Q, Jia X et al (2015b) Profiles of differential expression of circulating microRNAs in hepatitis B virus-positive small hepatocellular carcinoma. Cancer Biomark 15(2):171–180
Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun S et al (2008) miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 123(2):372–379
Yu X, Luo L, Wu Y, Yu X, Liu Y, Yu X et al (2013) Gastric juice miR-129 as a potential biomarker for screening gastric cancer. Med Oncol 30(1):365
Zang W, Wang Y, Du Y, Xuan X, Wang T, Li M et al (2014) Differential expression profiling of microRNAs and their potential involvement in esophageal squamous cell carcinoma. Tumour Biol 35(4):3295–3304
Zhang X, Cui L, Ye G, Zheng T, Song H, Xia T et al (2012) Gastric juice microRNA-421 is a new biomarker for screening gastric cancer. Tumour Biol 33(6):2349–2355
Zhu C, Ren C, Han J, Ding Y, Du J, Dai N et al (2014a) A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer. Br J Cancer 110(9):2291–2299
Zhu Y, Xia Y, Niu H, Chen Y (2014b) MiR-16 induced the suppression of cell apoptosis while promote proliferation in esophageal squamous cell carcinoma. Cell Physiol Biochem 33(5):1340–1348
Zhuang K, Han K, Tang H, Yin X, Zhang J, Zhang X et al (2016) Up-Regulation of Plasma miR-23b is Associated with Poor Prognosis of Gastric Cancer. Med Sci Monit 22:356–361
Acknowledgments
This study was supported by the National Nature Science Foundation of China (81573220), Jiangsu provincial Six Talent Peaks (WSN107), the Foundation of China Postdoctoral Studies (M2013541699), the Foundation of Jiangsu Province Postdoctoral Studies (1302149C) and the Foundation for Young Scholar in Yangzhou (YZ2014046).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Ren, C., Chen, H., Han, C. et al. High expression of miR-16 and miR-451 predicating better prognosis in patients with gastric cancer. J Cancer Res Clin Oncol 142, 2489–2496 (2016). https://doi.org/10.1007/s00432-016-2243-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-016-2243-z